11 June 2020

Smith+Nephew launches INTELLIO◊ Connected Tower Solution for improved operating room efficiency

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its new INTELLIO Connected Tower Solution which wirelessly connects and remotely controls multiple Sports Medicine systems from outside the sterile field.

Today’s surgical environments can be challenging to navigate in both hospitals and Ambulatory Surgery Centers (ASCs) where space is at a premium. The INTELLIO Connected Tower Solution uses a centralized app to wirelessly connect and control the major components of an arthroscopy surgical tower from outside the sterile field, helping to streamline procedure support. The integrated solution features a remote control, on-screen display optimized for surgeon workflow, and a cloud-based image management portal.

The components that make up Smith+Nephew’s INTELLIO Connected Tower Solution include:

“Smith+Nephew is committed to finding innovative new ways for our customers to maximize the value of their capital investments, while minimizing the amount of equipment in the OR,” said Scott Schaffner, SVP and General Manager, Sports Medicine at Smith+Nephew. “The INTELLIO Connected Tower Solution does this by simply integrating components and enabling them to work together - driving workflow efficiency and making it easier for healthcare professionals to do their jobs.”

 

Enquiries

Media

 

David Snyder

+1 978-749-1440

Smith+Nephew

 

 

 

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on TwitterLinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

References

1. Smith & Nephew, Inc. Testing Protocol Report 15007992

Title

Text